A detailed history of G&S Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, G&S Capital LLC holds 5,783 shares of ABBV stock, worth $1.17 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
5,783
Previous 5,731 0.91%
Holding current value
$1.17 Million
Previous $982,000 16.29%
% of portfolio
0.5%
Previous 0.42%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$163.84 - $199.33 $8,519 - $10,365
52 Added 0.91%
5,783 $1.14 Million
Q2 2024

Jul 30, 2024

SELL
$154.79 - $180.76 $16,562 - $19,341
-107 Reduced 1.83%
5,731 $982,000
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $13,105 - $14,932
-82 Reduced 1.39%
5,838 $1.06 Million
Q4 2023

Jan 26, 2024

BUY
$137.6 - $154.97 $18,576 - $20,920
135 Added 2.33%
5,920 $917,000
Q3 2023

Oct 12, 2023

BUY
$133.59 - $154.65 $8,950 - $10,361
67 Added 1.17%
5,785 $862,000
Q2 2023

Jul 26, 2023

SELL
$132.51 - $164.9 $338,430 - $421,154
-2,554 Reduced 30.88%
5,718 $770,000
Q1 2023

Apr 20, 2023

BUY
$144.61 - $166.54 $459,136 - $528,764
3,175 Added 62.29%
8,272 $1.32 Million
Q4 2022

Jan 20, 2023

BUY
$138.31 - $165.87 $68,463 - $82,105
495 Added 10.76%
5,097 $0
Q3 2022

Oct 21, 2022

BUY
$134.21 - $153.93 $43,886 - $50,335
327 Added 7.65%
4,602 $618,000
Q2 2022

Jul 21, 2022

BUY
$137.62 - $174.96 $30,689 - $39,016
223 Added 5.5%
4,275 $655,000
Q1 2022

Apr 15, 2022

SELL
$131.98 - $163.75 $9,106 - $11,298
-69 Reduced 1.67%
4,052 $657,000
Q4 2021

Jan 20, 2022

BUY
$107.43 - $135.93 $23,527 - $29,768
219 Added 5.61%
4,121 $558,000
Q3 2021

Oct 19, 2021

BUY
$106.4 - $120.78 $36,920 - $41,910
347 Added 9.76%
3,902 $421,000
Q2 2021

Jul 22, 2021

BUY
$105.21 - $117.21 $39,032 - $43,484
371 Added 11.65%
3,555 $400,000
Q1 2021

Apr 15, 2021

BUY
$102.3 - $112.62 $31,815 - $35,024
311 Added 10.82%
3,184 $345,000
Q4 2020

Jan 21, 2021

BUY
$80.49 - $108.67 $2,575 - $3,477
32 Added 1.13%
2,873 $308,000
Q3 2020

Oct 21, 2020

BUY
$85.91 - $100.83 $11,426 - $13,410
133 Added 4.91%
2,841 $249,000
Q2 2020

Jul 24, 2020

SELL
$73.37 - $98.18 $20,396 - $27,294
-278 Reduced 9.31%
2,708 $266,000
Q1 2020

Apr 23, 2020

BUY
$64.5 - $97.79 $2,451 - $3,716
38 Added 1.29%
2,986 $227,000
Q4 2019

Jan 21, 2020

BUY
$72.13 - $90.25 $9,593 - $12,003
133 Added 4.72%
2,948 $261,000
Q3 2019

Oct 17, 2019

BUY
$62.98 - $75.72 $19,271 - $23,170
306 Added 12.2%
2,815 $213,000
Q2 2019

Jul 19, 2019

SELL
$65.7 - $83.98 $16,359 - $20,911
-249 Reduced 9.03%
2,509 $182,000
Q1 2019

Apr 22, 2019

BUY
$77.14 - $90.79 $94,805 - $111,580
1,229 Added 80.38%
2,758 $222,000
Q4 2018

Jan 15, 2019

SELL
$77.85 - $96.01 $2.77 Million - $3.42 Million
-35,574 Reduced 95.88%
1,529 $141,000
Q3 2018

Oct 30, 2018

BUY
$88.91 - $98.84 $3.19 Million - $3.55 Million
35,892 Added 2963.83%
37,103 $3.51 Million
Q2 2018

Aug 01, 2018

BUY
$89.78 - $106.23 $11,491 - $13,597
128 Added 11.82%
1,211 $112,000
Q1 2018

Apr 25, 2018

BUY
$92.01 - $123.21 $26,406 - $35,361
287 Added 36.06%
1,083 $102,000
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $71,289 - $78,175
796
796 $77,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track G&S Capital LLC Portfolio

Follow G&S Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of G&S Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on G&S Capital LLC with notifications on news.